Legal & General UCITS ETF PLC - L&G Healthcare Breakthrough UCITS ETF AccumUSD (GB:DOCT) Price & Chart

Moderna (MRNA) outlined the next phase of growth at its 2026 Analyst Day, highlighting how more than a decade of investment in the Company’s mRNA platform has enabled the development

Moderna (MRNA) expects 2026 revenue growth of 15% to 25%, compared with the original outlook of up to 10%, and is on track to achieve approximately 10 percentage points of

Option traders moderately bearish in Moderna (MRNA), with shares down $2.73 near $248.10. Options volume relatively light with 72k contracts traded and puts leading calls for a put/call ratio of

Moderna (MRNA) announced the publication of results from a large real-world study evaluating the comparative effectiveness of mNEXSPIKE and Comirnaty among U.S. Veterans aged 65 years and older during the

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Regeneron, retaining the price target of $1,175.00. John Newman’s rating is based on several factors supporting Regeneron’s long-term growth

Thermo Fisher ($TMO), Eli Lilly & Co ($LLY), and GE Aerospace ($GE) are three mega-cap stocks with a Perfect 10 Smart Score. The TipRanks Smart Score measures stocks on eight

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will be moving and why. Published

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Regeneron. The associated price target remains the same with $1,030.00. Tazeen Ahmad’s rating is based on

Piper Sandler analyst David Westenberg initiated coverage of CareDx (CDNA) with an Overweight rating and $100 price target The market underestimates the company’s ability to grow beyond annual transplant volumes